Calyxo
Pleasanton, US · Founded 2016 · Delaware corporation · 1 known investors
Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared. The company serves urologists and patients seeking routine, single-treatment kidney stone management.
Founders & leadership
JC
Joe CataneseExecutive Officer, Director
CB
Chris BuchkoExecutive Officer
DH
Douglas HughesExecutive Officer, Director
JS
Jee ShinExecutive Officer, Director
RC
Robert Calvin GoforthDirector
MK
Mark KiddExecutive Officer
RD
Ryan DrantDirector
JG
Jacob GarfieldDirector
DA
Dave AmersonDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$40.1MraisedApr 2026 · 12 investors · Other Health CareRule 506(b)
▶$40.1MraisedApr 2026 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Douglas HughesExecutive Officer, Director
- Jee ShinExecutive Officer, Director
- Joe CataneseExecutive Officer, Director
- Jacob GarfieldDirector
- Dave AmersonDirector
- Ryan DrantDirector
- Chris BuchkoExecutive Officer
- Dana G. MeadDirector
- Offering amount
- $40.1M
- Amount sold
- $40.1M
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$28.3MraisedDec 2024 · 10 investors · Other Health CareRule 506(b)
▶$28.3MraisedDec 2024 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joe CataneseExecutive Officer, Director
- Chris BuchkoExecutive Officer
- Dave AmersonDirector
- Douglas HughesExecutive Officer, Director
- Ryan DrantDirector
- Jee ShinExecutive Officer, Director
- Jacob GarfieldDirector
- Offering amount
- $32M
- Amount sold
- $28.3M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedNov 2023 · 16 investors · Other Health CareRule 506(b)
▶$50MraisedNov 2023 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ryan DrantDirector
- Douglas HughesExecutive Officer, Director
- Jee ShinExecutive Officer, Director
- Dave AmersonDirector
- Joe CataneseExecutive Officer, Director
- Chris BuchkoExecutive Officer
- Jacob GarfieldDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.7MraisedFeb 2022 · 18 investors · Other Health CareRule 506(b)
▶$22.7MraisedFeb 2022 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Douglas HughesExecutive Officer, Director
- Joe CataneseExecutive Officer, Director
- Jee ShinExecutive Officer, Director
- Chris BuchkoExecutive Officer
- Ryan DrantDirector
- Dave AmersonDirector
- Offering amount
- $22.7M
- Amount sold
- $22.7M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.9MraisedOct 2019 · 20 investors · Other Health CareRule 506(b)
▶$12.9MraisedOct 2019 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jee ShinExecutive Officer, Director
- Ryan DrantDirector
- Robert Calvin GoforthDirector
- Beverly HussDirector
- Douglas HughesDirector
- Offering amount
- $15.9M
- Amount sold
- $12.9M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$450KraisedMay 2019 · 17 investors · Other Health CareRule 506(b)
▶$450KraisedMay 2019 · 17 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jee ShinExecutive Officer, Director
- Beverly HussDirector
- Douglas HughesDirector
- Robert Calvin GoforthDirector
- Offering amount
- $1M
- Amount sold
- $450K
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1.6MraisedAug 2018 · 50 investors · BiotechnologyRule 506(b)
▶$1.6MraisedAug 2018 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas HughesDirector
- Robert Calvin GoforthDirector
- Jee ShinExecutive Officer, Director
- Offering amount
- $1.7M
- Amount sold
- $1.6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$30KraisedSep 2017 · 2 investors · OtherRule 506(b)
▶$30KraisedSep 2017 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jee ShinExecutive Officer, Director
- Mark KiddExecutive Officer
- Robert Calvin GoforthDirector
- Offering amount
- $150K
- Amount sold
- $30K
- Minimum investment
- $10K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Careers - Calyxocalyxoinc.com · 2026
- Calyxo raises $40m to advance kidney stone removal systemfinance.yahoo.com · 2026
- Calyxo Secures $40 Million Series F Financing as CVAC System Surpasses 40,000 Patients Treated for Kidney Stone Removalbusinesswire.com · 2026
- Calyxo Secures $40M in Series F Fundingfinsmes.com · 2026
- Sell or Invest in Calyxo Stock Pre-IPOnasdaqprivatemarket.com · 2025
- Calyxo Raises $50M in Series D Fundingfinsmes.com · 2023